Humira To Compete With Remicade, Enbrel in Ankylosing Spondylitis
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA approved Abbott’s adalimumab for reducing signs and symptoms in patients with active ankylosing spondylitis.
You may also be interested in...
Humira Cleared For Additional Psoriatic Arthritis Indication
Broadened indication for inhibiting structural joint damage matches Enbrel and Remicade indications.
Humira Cleared For Additional Psoriatic Arthritis Indication
Broadened indication for inhibiting structural joint damage matches Enbrel and Remicade indications.
Wyeth Boosting TNF Inhibitor R&D Via Ablynx Deal
Discovery and development deal for Ablynx’ preclinical Nanobodies could build on Wyeth’s experience with Enbrel.